Key result
Among patients treated with Absorb bioresorbable vascular scaffolds, diabetes mellitus was associated with a higher 1-year rate of target lesion failure compared to non-diabetics (7.8% vs 4.3%).
Why the study?
Data on the clinical performance of bioresorbable scaffolds in patients with diabetes mellitus are still limited.
Cohort (n=1,477)
Yes
Answers are grounded in this paper and cite their sources.
DM warrants closer post-Absorb surveillance; leaves open whether risk is scaffold-specific versus general diabetic vasculopathy.
BACKGROUND: Data on the clinical performance of bioresorbable scaffolds in patients with diabetes mellitus (DM) are still limited. The present study reported 1-year clinical outcomes associated with the use of everolimus-eluting bioresorbable vascular scaffolds (Absorb BVS; Abbott Vascular, Santa Clara, CA) in DM patients. METHODS AND RESULTS: This was a subanalysis from the GHOST-EU (Gauging coronary Healing with biOresorbable Scaffolding plaTforms in Europe) multicenter retrospective registry including patients treated with Absorb BVS between November 2011 and September 2014. In this study, a comparative analysis stratified according to DM was performed. The primary endpoint was target lesion failure (TLF), defined as the combination of cardiac death, target-vessel myocardial infarction (MI) and clinically-driven target-lesion revascularization (TLR). A total of 1,477 patients were treated with 2,224 Absorb BVS; 381 (25.8%) and 1,096 (74.2%) patients were with and without DM, respectively. The 1-year rate of TLF was higher among patients with DM (7.8%) than those without DM (4.3%); the increase in TLF was driven by TLR (6.5% vs. 3.3%, P = 0.009); no significant differences in cardiac death (1.1% vs. 0.9%, P = 0.68) and target-vessel MI (3.1% vs. 2.2%, P = 0.38) were observed, respectively. Definite/probable scaffold thrombosis rate tended to be higher among patients with DM than those without DM (3.0% vs. 1.7%, P = 0.14, respectively). CONCLUSIONS: Absorb BVS use in patients with DM was associated with increased 1-year TLF and scaffold thrombosis compared with non-diabetes patients.
No takes yet. Share an insight, caveat, or question.
Capranzano et al. (2017) conducted a cohort in Patients requiring coronary stenting/scaffolding (n=1,477). Diabetes mellitus vs. No diabetes mellitus was evaluated on Target lesion failure (TLF), defined as cardiac death, target-vessel myocardial infarction, and clinically-driven target-lesion revascularization. Among patients treated with Absorb bioresorbable vascular scaffolds, diabetes mellitus was associated with a higher 1-year rate of target lesion failure compared to non-diabetics (7.8% vs 4.3%).
Synapse has enriched 10 related papers. Consider them for comparative context: